FindTrial
Sign In

Inhaled nitric oxide (iNO) therapy for preterm infants after 7 days of age: a scoping review

Inhaled nitric oxide (iNO) therapy for preterm infants after 7 days of age: a scoping review - Inhaled nitric oxide (iNO) therapy for preterm infants after 7 days of age: a scoping review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051498
Enrollment
Unknown
Registered
2023-07-01
Start date
2023-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary dysplasia (BPD), Pulmonary hypertension, Neonatal hypoxic respiratory failure

Interventions

None listed

Sponsors

Kitasato University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: i) Preterm infants <37 weeks' gestation treated with iNO after 7 days of life ii) Published between 2003 and 2022 iii) Conducted among developed countries iv) Published in English or Japanese v) Randomized controlled trial, cohort study, case-control study, and case series

Exclusion criteria

Exclusion criteria: i) Infants born more than 37 weeks of gestational age ii) Initiation of iNO is before 7 days of life iii) Infants with congenital malformation syndrome and a chromosomal abnormality iv) Animal and in-vitro studies

Design outcomes

Primary

MeasureTime frame
Initiation criteria of iNO—

Secondary

MeasureTime frame
postnatal day of the iNO initiation, iNO concentration (ppm), duration of iNO, discontinuation criteria of iNO, other drugs, adverse effects—

Countries

Japan

Contacts

Public ContactHidehiko Nakanishi

Kitasato University Neonatology

n0n.hide@med.kitasato-u.ac.jp+81-42-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026